These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 15853440)

  • 21. Post-marketing drug withdrawals: Pharmacovigilance success, regulatory problems.
    Aronson JK
    Therapie; 2017 Oct; 72(5):555-561. PubMed ID: 28461037
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The ISoP CommSIG for Improving Medicinal Product Risk Communication: A New Special Interest Group of the International Society of Pharmacovigilance.
    Bahri P; Dodoo AN; Edwards BD; Edwards IR; Fermont I; Hagemann U; Hartigan-Go K; Hugman B; Mol PG
    Drug Saf; 2015 Jul; 38(7):621-7. PubMed ID: 26032946
    [No Abstract]   [Full Text] [Related]  

  • 23. Pharmacogenovigilance: a pharmacogenomics pharmacovigilance program.
    Awada Z; Zgheib NK
    Pharmacogenomics; 2014 Apr; 15(6):845-56. PubMed ID: 24897290
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A survey of spontaneous reporting of adverse drug reactions in 10 years of activity in a pharmacovigilance centre in Portugal.
    Marques J; Ribeiro-Vaz I; Pereira AC; Polónia J
    Int J Pharm Pract; 2014 Aug; 22(4):275-82. PubMed ID: 24188533
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The Patient's Voice in Pharmacovigilance: Pragmatic Approaches to Building a Patient-Centric Drug Safety Organization.
    Smith MY; Benattia I
    Drug Saf; 2016 Sep; 39(9):779-85. PubMed ID: 27098248
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Pharmacovigilance in Israel - tools, processes, and actions.
    Schwartzberg E; Berkovitch M; Dil Nahlieli D; Nathan J; Gorelik E
    Isr J Health Policy Res; 2017 Aug; 6(1):29. PubMed ID: 28760141
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Capacity for a global vaccine safety system: the perspective of national regulatory authorities.
    Graham JE; Borda-Rodriguez A; Huzair F; Zinck E
    Vaccine; 2012 Jul; 30(33):4953-9. PubMed ID: 22658930
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Consumer reporting of adverse drug reactions: Systems that allow patients to report side effects of the drugs they are taking have yielded valuable information for improving drugs safety and health care.
    Weigmann K
    EMBO Rep; 2016 Jul; 17(7):949-52. PubMed ID: 27198546
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Patients' Perspectives on Adverse Drug Reaction Reporting in a Developing Country: A Case Study from Ghana.
    Sabblah GT; Darko DM; Mogtari H; Härmark L; van Puijenbroek E
    Drug Saf; 2017 Oct; 40(10):911-921. PubMed ID: 28653291
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Can Patient Safety Incident Reports Be Used to Compare Hospital Safety? Results from a Quantitative Analysis of the English National Reporting and Learning System Data.
    Howell AM; Burns EM; Bouras G; Donaldson LJ; Athanasiou T; Darzi A
    PLoS One; 2015; 10(12):e0144107. PubMed ID: 26650823
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Safe Use of Recent New Drugs-Current Status and Challenges].
    Ohashi Y
    Yakugaku Zasshi; 2018; 138(2):177-183. PubMed ID: 29386431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Active pharmacovigilance in China: recent development and future perspectives.
    Li X; Li H; Deng J; Zhu F; Liu Y; Chen W; Yue Z; Ren X; Xia J
    Eur J Clin Pharmacol; 2018 Jul; 74(7):863-871. PubMed ID: 29637279
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacovigilance in resource-limited countries.
    Olsson S; Pal SN; Dodoo A
    Expert Rev Clin Pharmacol; 2015; 8(4):449-60. PubMed ID: 26041035
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
    Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
    Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Adverse drug reactions reporting in Calabria (Southern Italy) in the four-year period 2011-2014: impact of a regional pharmacovigilance project in light of the new European Legislation.
    Leporini C; Marrazzo G; Mumoli L; Esposito S; Gallelli L; Mangano G; Brancati G; De Francesco EA; Russo E; De Sarro G;
    Expert Opin Drug Saf; 2017 May; 16(5):515-522. PubMed ID: 28395523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What can consumer adverse drug reaction reporting add to existing health professional-based systems? Focus on the developing world.
    Fernandopulle RB; Weerasuriya K
    Drug Saf; 2003; 26(4):219-25. PubMed ID: 12608886
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacovigilance activities in ASEAN countries.
    Suwankesawong W; Dhippayom T; Tan-Koi WC; Kongkaew C
    Pharmacoepidemiol Drug Saf; 2016 Sep; 25(9):1061-9. PubMed ID: 27174034
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [The Spanish National Health System patient safety strategy, results for the period 2005-2007].
    Terol E; Agra Y; Fernández-Maíllo MM; Casal J; Sierra E; Bandrés B; García MJ; del Peso P
    Med Clin (Barc); 2008 Dec; 131 Suppl 3():4-11. PubMed ID: 19572447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pharmacovigilance and communicating safety information.
    Drug Ther Bull; 2012 Dec; 50(12):138-40. PubMed ID: 23241564
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.